Intelligence · Clinical Pipeline
Vir Biotechnology Pipeline
All ClinicalTrials.gov programs at Vir Biotechnology — phase, modality, and trial IDs.
- Programs
- 10
Quick answer
Vir Biotechnology has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic HER2-Expressing Cancers
Vir Biotechnology
Participants with Locally Advanced or Metastatic HER2-Expressing Cancers
1 trial -
Sotrovimab
Vir Biotechnology
COVID-19 Infection
1 trial -
VIR-1111
Vir Biotechnology
HIV I Infection
1 trial -
VIR-2218
Vir Biotechnology
Hepatic Impairment
1 trial -
VIR-2218
Vir Biotechnology
Renal Impairment
1 trial -
VIR-2482
Vir Biotechnology
Influenza A
1 trial -
VIR-3434
Vir Biotechnology
Chronic Hepatitis B
1 trial -
VIR-5500
Vir Biotechnology
Hormone-refractory Prostate Cancer
1 trial -
VIR-5525
Vir Biotechnology
Solid Tumor Malignancies
1 trial -
VRON-0200-AdC6
Vir Biotechnology
Chronic Hepatitis B
1 trial
Frequently asked questions
How many pipeline programs does Vir Biotechnology have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs